|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/00 | |
| C07K 16/00 | |||
| C07K 16/12 |
| (11) | Number of the document | 1761561 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05711847.3 |
| Date of filing the European patent application | 2005-01-20 | |
| (97) | Date of publication of the European application | 2007-03-14 |
| (45) | Date of publication and mention of the grant of the patent | 2015-08-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2005/002072 |
| Date | 2005-01-20 |
| (87) | Number | WO 2005/069970 |
| Date | 2005-08-04 |
| (30) | Number | Date | Country code |
| 537364 P | 2004-01-20 | US | |
| 546216 P | 2004-02-23 | US |
| (72) |
FLYNN, Peter, US
LUEHRSEN, Kenneth, US
BALINT, Robert, F., US
HER, Jeng-Horng, US
BEBBINGTON, Christopher, R., US
YARRANTON, Geoffrey, T., US
|
| (73) |
KaloBios Pharmaceuticals, Inc.,
442 Littlefield Avenue, South San Francisco, CA 94080,
US
|
| (54) | ANTIBODY SPECIFICITY TRANSFER USING MINIMAL ESSENTIAL BINDING DETERMINANTS |
| ANTIBODY SPECIFICITY TRANSFER USING MINIMAL ESSENTIAL BINDING DETERMINANTS |